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Abstract High molecular weight alginate beads with
59% mannuronic acid content or 68% guluronic acid were
prepared using a droplet generator and crosslinked in cal-
cium chloride. The alginate beads were compared to cur-
rent embolisation microspheres for compressibility and
monitored over 12 weeks for size and weight change at
37C in low volumes of ringers solutions. A sheep uterine
model was used to analyse bead degradation and inﬂam-
matory response over 12 weeks. Both the in vitro and in
vivo data show good delivery, with a compressibility
similar to current embolic beads. In vitro, swelling was
noted almost immediately and after 12 weeks the ﬁrst signs
of degradation were noted. No difference was noted in
vivo. This study has shown that high molecular weight
alginate gel beads were well tolerated by the body, but
beads associated with induced thrombi were susceptible to
inﬂammatory cell inﬁltration. The beads were shown to be
easy to handle and were still observable after 3 months in
vivo. The beads were robust enough to be delivered
through a 2.7 Fr microcatheter. This study has demon-
strated that high molecular weight, high purity alginate
bead can be considered as semi-permanent embolisation
beads, with the potential to bioresorb over time.
1 Introduction
Polysaccharides, such as alginates, are widely used in food,
cosmetic and medical ﬁelds due to their structural proper-
ties, biocompatibility and safety. When alginate is com-
bined with divalent cations a hydrogel is formed that
exhibits a level of biocompatibility that can encapsulate
cells [1]. Previous studies have shown that purity can affect
the biocompatibility of alginate implants [2]. Alginate is a
copolymer composed of mannuronate (M) and guluronate
(G) stereomonomers [3, 4]. The afﬁnity of a divalent cation
(i.e. calcium) is stronger for G isomers due to the steric
arrangement of the atoms [4, 5]. Two G monomers form an
‘‘egg-box’’ in which a calcium ion sits and crosslinks two
polymer chains [4]. Consequently the M:G ratio will effect
the crosslinking capacity and thus the physical properties
of a calcium alginate gel [6].
Alginate is also a biodegradable polymer; the backbone
can be degraded via hydrolysis of the glycosidic bonds [7]
or an alginate gel can dissolve due to the elution of the
cross-linking calcium cation [6]. Molecular weight has
been shown to affect alginate polymer chain degradation
[8] and the elution of the crosslinking calcium can also lead
to dissolution of gel [9]. This paper considers both high M
and high G calcium crosslinked alginate gel beads as
devices for use in embolisation.
Therapeutic embolisation is the intentional introduction
of a (foreign) embolic material into a blood vessel in order
to reduce or completely obstruct the blood ﬂow. This
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tumours and arteriovenous malformations (AVMs). The
choice of embolic agent depends on the desired level of
occlusion down the vascular tree and permanency. The
ideal occlusion technique is one that allows for accurate
guidance and delivery to the target with low risk of injury
to normal structures. To achieve this, interventional radi-
ologists (IRs) are of the opinion that the embolic agent
requires a combination of a number of attributes [10]. In
handling the agent, it must be either radiopaque or have the
ability to be mixed into a radiopaque suspension to enable
visualisation during delivery. Simplicity and reliability of
delivery is preferred (glue is notoriously difﬁcult to handle
for instance), without blocking of the catheters used to
deliver the agents. Adaptability to allow selective and rapid
occlusion of various blood vessels sizes and types is
desirable; and an ability to reach distal vascular beds is
particularly important in the treatment of tumours. If pos-
sible, the agent should have amenability to trouble shoot-
ing/salvage in case of complications or device malfunction.
Other important considerations include biocompatibility
and cost competitiveness.
One important and growing area of embolotherapy is
uterine artery embolisation (UAE), or sometimes referred
to as uterine ﬁbroid embolisation (UFE). Since its ﬁst
report in 1995 [11] it is estimated that more that 100,000
UAE procedures have been performed (mainly in the
USA and Europe) [12]. Outcomes from a large US reg-
istry [13] and four separate (albeit relatively small) ran-
domised trials over the last few years [14–17]
demonstrate that UAE is safe and effective, gives similar
results to hysterectomy but with faster and shorter
recovery and uterine preservation. This is balanced
against the need to retreat some patients following UAE.
Given that some patients opt for UAE as they wish to
maintain the potential for future pregnancy, there is some
debate over whether the embolisation agent should be
permanent or temporary in nature. Gelatin sponge (or
Gelfoam
) provides the only current degradable option,
which is non-calibrated, has an irreproducible degradation
rate and can induce a strong inﬂammatory response. A
calibrated microspherical embolisation agent with con-
trolled degradability could therefore fulﬁl a role in the
clinical practice of UAE.
This paper reports the results from some in vitro and in
vivo models used to assess all the key necessary attributes
of alginate beads as an embolisation device. The in vitro
tests examined bead compressibility compared to other
embolic beads on the market, microcatheter deliverability
and bead degradation. A sheep uterine artery embolisation
model, designed to mimic UAE conditions, was used to
assess bead deliverability, biocompatibility and degrada-
tion over 12 weeks in vivo.
2 Experimental
2.1 Materials
Dry kelp is used for the production of Phycomer (CellMed
AG, Alzenau, Germany), a highly puriﬁed sodium alginate
with a markedly low impurity proﬁle, made by a proprie-
tary patented puriﬁcation process [18]. Phycomer E01, a
high M alginate with a mannuronic acid content about
59%, is isolated from the brown algae species Laminaria
pallida. It has a molecular weight of greater than
800,000 g/mol with a typical viscosity of a 0.2% w/v
solution being 10–60 mPa.s. Phycomer E01 has properties
ideally suited for the production of soft, biodegradable non-
permanent implants.
Phycomer C01, which is isolated from Laminaria hy-
perborea, is a high G alginate with a guluronic acid content
about 68% and a molecular weight of around 400,000 g/
mol, producing a 0.2% w/v solution viscosity of 5–
13 mPa.s. Phycomer C01 forms stiffer gels with tighter
pores than Phycomer E01 and is used for the immunoiso-
lation of cellular implants, such as GLP-1 producing
CellBeads which are under clinical evaluation for the
treatment of haemorrhagic stroke [19] and pre-clinical
evaluation for the treatment of acute myocardial infarction
[20].
The beads used in the compressibility comparison tests
were 900–1200 lm Bead Block
TM; (Biocompatibles UK
Ltd, UK), 900–1200 lm DC Bead
TM; (Biocompatibles UK
Ltd, UK), 900–1200 lm Embosphere
 (Biosphere Medical
Inc., USA) and Countour SE
TM (Boston Scientiﬁc Inc.
USA).
2.2 Methods
2.2.1 Bead preparation
The beads were prepared by dissolving high molecular
weight sodium alginate at a concentration of 0.6% (w/v) in
saline. Using a droplet generator similar to that described
elsewhere [21], a stream of the alginate solution was
injected through a needle bore using a motorized syringe
and cut using a jet of hydrated compressed air, forming
small alginate solution droplets. The solution droplets were
crosslinked in a 100 mM calcium chloride solution placed
underneath the syringe. Bead diameter could be controlled
by varying key parameters such as the solution injection
rate, airﬂow and needle size. The mean diameters (±SD) of
the beads used in most experiments were 506 lm
(±18 lm) and 506 lm( ±21 lm) in Ringers solution for
high G and high M beads respectively. Larger beads made
using the same procedure were generated for compression
testing. All beads were produced under aseptic conditions
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such as irradiation cause degradation of the alginate and
affect its ability to gel [22].
2.2.2 Compression testing
The required force necessary to compress the alginate
beads was assessed using a ﬂat 5 mm cylindrical probe
attached to an Instron Materials Testing Systems Model
4411 (Instron High Wycombe, UK) mounted with a 50 N
load cell. A close packed monolayer of beads (900–
1100 lm) in Ringers solution was placed on a ﬂat surface
underneath the probe. Excess Ringers solution was wicked
from the sample using a tissue. The probe was positioned
1.2 mm above the plate. The probe was then extended by
0.85 mm at a speed of 5 mm/min and the load data was
recorded. The modulus was calculated from the initial
compression gradient of a stress/strain plot of the com-
pression force. Since the resistivity of a hydrogel to com-
pression is sensitive to conditions such as humidity and
temperature all beads were tested within 2 h of each other
to minimise these effects. Commercially available embolic
microspheres were tested for comparison. The embolic
beads tested were High G alginate, High M alginate, DC
Bead, BeadBlock, Contour SE and Embosphere.
2.2.3 Deliverability (in vitro)
In order to assess simplicity of delivery technique and
reliability of the delivery mechanism, each of the bead
formulations were delivered down a Progreat 2.7 Fr cath-
eter (Teumo, Japan) three times. Alginate gel beads were
suspended at a 1/10 dilution in a 50:50 mix of saline (0.9%)
and contrast medium (Omnipaque, GE Healthcare, USA).
Each solution was placed on a roller mixer for 3–5 min.
Half of the sample volume was drawn into a reservoir luer
lock syringe; this was connected to a three way connector
and thoroughly mixed with an attached 3 ml delivery syr-
inge. Post mixing, the product was drawn and delivered
from the 3 ml syringe. Once delivered a further two 3 ml
aliquots were drawn, mixed and delivered.
The delivery was scored using a 0–5 scoring system (0
indicating a saline like delivery and 5 indicating a complete
blockage). The catheter was then ﬂushed with saline and
the process was repeated with the second half of the bead/
solution mix. Post delivery the beads were assessed for
bead fragmentation using an Olympus phase contrast
microscope.
2.2.4 Degradation (in vitro)
Alginate gel bead degradation analysis was monitored in
vitro by measuring the elution of calcium from the beads
using ion chromatography (IC) and size/weight change of
the hydrated beads using an Olympus phase contrast
microscope. To mimic the minimal ﬂuid embolic bead
would be exposed to in an embolic environment in vivo,
only 1 ml Ringers solution was placed in a centrifuge tube
with 0.5 ml alginate beads measured into centrifuge inserts
with 5 lm pores (Ultrafree-MC PVDF durapore; Millipore,
UK). The samples were placed in an oven at 37C until a
testing time point, when the samples were centrifuged
(JOUAN CR312, Paris, France) at 300G for 5 min. The
solution collected after centrifuging was kept for IC anal-
ysis. The remaining hydrated spheres were weighed using a
microbalance and 1 ml Ringers solution was added.
2.2.5 Sheep uterine arterial embolisation model
2.2.5.1 Species The ﬁve animals used in this study were
non-pregnant female sheep aged between 2 and 5 years.
The breed was Blanche du Massif Central. The sheep each
weighed between 40 and 60 kg at the beginning of the
study.
2.2.5.2 Ethics The study was conducted at Biomatech
SAS, France and was approved by Biomatech Ethical
Committee prior to implementation. The animals were kept
in conditions which conformed to the requirements of farm
animals under ECC directive 86/906.
2.2.5.3 Procedure In order to obtain an arterial size in
sheep similar to that of a woman with uterine ﬁbroids,
hormonal control was required [23]. The menstrual cycle of
the sheep was controlled by inserting a sponge impregnated
with 40 mg Chronolone (Chrono-gest
 Esponge; Intervet,
France) inside the vagina of the animal. After 13 days the
sponge was removed, and an intramuscular injection of
500 IU of serum derived gonadotropin (Chrono-gest

PMSG; Intervet, France) was administered to achieve
ovulation. Pelvic angiography and embolisation of the
uterine arteries was then performed within 24 h of the
injection. The animals were fasted 24 h prior to the
procedure.
Embolisation beads (1 ml) were supplied sterile in vials
and were mixed with contrast agent prior to embolisation.
The beads were suspended at a dilution of 1/10 in a 50:50
mixture of contrast agent and saline in a ﬁnal volume of
10 ml and gently shaken to homogenize the suspension.
This was then split into two 5 ml syringes, one for each
feeding artery. A total of 0.5 ml of beads in a 5 ml sus-
pension was used for the embolisation of each uterine
artery (this is equivalent to approximately 5000 beads).
This volume was selected in order to induce minimal
necrosis of the organ and hence allow a proper assessment
of the inﬂammatory response to the beads. The injection
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123was performed slowly under ﬂuoroscopic control. After
injection of embolic agent, the catheter was purged with
approximately 3 ml of saline. The surgery was performed
under angiography (Philips BV212). The study did not
fully embolise the uterus as this may have impeded
assessment of the other factors or caused premature death,
by inducing too much tissue necrosis.
One feeding artery was used per test article as shown in
Table 1. Animals were killed at 1 week (n = 1, 1 feeding
artery per test article), 4 weeks (n = 2, 2 feeding arteries
per test article) or 12 weeks (n = 2, 2 feeding arteries per
test article) after embolisation by lethal injection of bar-
biturate (Dolethal
, VETOQUINOL, France).
The uterus, ovaries and local lymph nodes were sampled
to allow for the gross and histological examination of the
cervix, body and horn.
2.2.5.4 Deliverability (in vivo) Assessments were made
at the time of the embolisation procedure: ease of appli-
cation and handling, reﬂux or adverse effects at the time of
embolisation, duration of embolisation and bead volume
injected.
2.2.6 In vivo analysis procedures
2.2.6.1 Histological analysis For each level (of the cer-
vix, body and horn segment) one slice was ﬁxed in 10%
buffered formalin and the second slice was ﬁxed in Car-
noys ﬁxative. Carnoys ﬁxative consists of 60% ethanol,
30% chloroform and 10% gluteraldehyde and was used
because formalin has been reported to dissolve alginate
gels [24]. Formalin was still also used as higher sample
resolution can be obtained. The tissues were then processed
by means of parafﬁn embedding. Safranin-hematoxylin-
eosin staining was performed. Where beads were found in
the histological sections the samples were analysed for
signs of inﬂammation and necrosis.
2.2.6.2 Degradation and distribution Using the histo-
logical slides, the beads were noted for signs of degradation
in relation to the length of time that they had been in the
animals. Possible signs of degradation or resorption were
determined as including (i) the presence of cellular inﬁl-
tration in the bead surface, (ii) the presence of alginate
material within the cytoplasm of giant cells and macro-
phages, (iii) the surface roughness of the bead.
3 Results and discussion
3.1 Compressibility
Figure 1 shows the comparative moduli (kPa) required to
compress various beads. The trend observed is the same as
that seen by other compression tests in the literature [25].
There is no statistical signiﬁcance (P[0.05; Bonferonni
corrected Student’s t-test) between High M and High G
alginate beads. Alginate beads are most similar in com-
pressibility to Bead Block (Bonferroni corrected Student’s
t-test, P[0.05 (G); P[0.05 (M)).
3.2 Deliverability
The compressibility analysis of the alginate beads indicated
that the delivery should be similar to beads already on the
market. However whilst the compressibility was similar,
the compressibility method does not establish the robust-
ness, fragmentation potential or elastic recovery speed of
the beads. In order to establish these properties, it was
necessary to test the beads in a clinically relevant scenario.
This was achieved by forcing the beads through a 2.7 Fr
Progreat microcatheter that is commonly used in emboli-
sation procedures. Images of the alginate beads post
delivery can be seen in Fig. 2.
The in vitro delivery of the alginate beads in omnipaque
contrast media, offered some resistance with an average
score of 2.5 when being delivered through the catheter.
When beads had already been delivered in the catheter
lumen and the catheter was not ﬂushed with saline, slightly
higher resistance was felt during the next bead injection;
with a delivery score of 2. No fragmentation was noted for
both high M and high G beads.
The delivery of the beads in the sheep uterine artery
embolisation model was quite similar for the two arteries to
be embolised respectively; 9.8 s ± 3.0 (SD) for the left and
10.2 s ± 3.9 (SD) for the right artery showing consistency.
The mean score calculation for those parameters per type
of bead did not show marked difference (Table 2). All
radiologists graded both bead types as good with regards to
their ease of handling and application This was consistent
with the in vitro assessment. In addition the embolisation
times were very similar for all injections (&10 s); another
demonstration of facile delivery. Further analysis of the
data showed that any variation in the duration of injection
was attributable to the surgeon that performed the injection
on the day rather than to the beads themselves (Student’s t-
test, P\0.05). Moreover, regardless of the interventional
Table 1 Table showing the number of uterine feeding arteries (n)
used in each test group and the corresponding beads that were injected
Bead type Duration of live exposure to alginate gel bead
1 week 4 weeks 12 weeks
High G n = 1 n = 2 n = 2
High M n = 1 n = 2 n = 2
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123radiologist used, had there been a blockage the time taken
to inject the beads would have increased noticeably com-
pared to the average for that user. No catheter blockages
occurred during any of the procedures.
3.3 Bead degradation
3.3.1 In vitro: size, shape and weight change
The weight change of the centrifuged hydrated beads
(Fig. 3a) followed a similar proﬁle to as the size difference
(Fig. 3b). Both showed an increase during the ﬁrst week in
Ringers solution and then began to decrease after 4 weeks.
High M beads showed greater size and weight increase
than high G.
3.3.2 In vivo: gross examination
At ﬁrst week a slight reddening of the uterus was observed
and attributed to embolisation induced necrosis. Clear
macroscopic signs of necrosis or inﬂammatory reaction
could not be observed in the gross specimens for the 4 and
12 week time period. The lack of any reddening at 4 and
12 weeks as attributed to the embolised areas ﬁnding new
blood supplies as a result of the small bead volumes used.
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Fig. 1 Modulus of M and G
alginate beads alongside
commercially-available embolic
beads (n = 5; ±SD). Alginate
beads are most similar in
compressibility to Bead Block
(Bonferroni corrected Student’s
t-test, P[0.05 (G); P[0.05
(M))
Fig. 2 Phase contrast image of
high G (left) and high M (right)
beads post catheter delivery. No
fragmentation was observed
Table 2 Occlusion times and potential to restore the blood vessel of embolic materials used in transcatheter embolisation [23]
Material Vessel size Duration of occlusion Potential for restoring
vascular continuity
Autologous blood clot Branch artery 8–24 h Excellent
Gelfoam particles Arterioles 2–3 weeks Good
Gelfoam powder Capillary bed C3 weeks Poor
Ivalon (PVA, dehydrated particles) Small Arteries Semi-permanent Limited
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1233.3.3 In vivo: histopathological analysis
Generally, beads were detected in one of four environ-
ments. The bead was found either completely occluding an
artery or within an artery surrounded by white space. The
white space is likely to be due to the bead dehydrating
during the processing step [26]. The third environment
where the presence of beads was detected was the obser-
vation of a circular space left behind within an artery. The
presence of a bead was shown by the compression of the
intima and media arterial layers; non-embolised arteries of
a similar size have thicker walls and non-circular elastic
lumen. In some instances the presence of a bead was
apparent through the observation of a circular gap in the
thrombus within an artery. The beads were sometimes
observed in a combination of these situations and were not
always observed as single beads. On occasion a longitu-
dinal cut of an artery would reveal a line of beads or a
cluster of beads could be detected in a larger artery.
The alginate beads within the arterial lumen are not nec-
essarily spherical because the slice cannot always be taken
perpendicular to the artery. Beads may seem elongated or
misshapen if the section had been taken at a non-
perpendicularangle.Inadditionoddshapesmaybeobserved
if the slice was taken at an arterial junction. Also, the pro-
cessingofthetissueandthinhistologysectionsmeanthatthe
likelihood of observing a bead is small and consequently
only few beads were observed in all of the sections. It is
worth noting that the lack of any beads does not necessarily
mean that any were lost through degradation.
The extent of necrosis and inﬂammation observed for
the samples was assessed and scored on a simple three-
grade scale (grade 0 = absent, grade 1 = moderate (\50%
of the observed area), grade 2 = extensive ([50% of the
observed area). At ﬁrst week, the mean necrosis score was
only 0.46 ± 0.71, indicating less than moderate necrosis;
this is to be expected given the small amount of embolic
used was regulated to limit the degree of necrosis occur-
ring. Necrosis was indicated by light-pink staining under
H&E of a largely acellular nature with lack of visible
nuclei, mostly associated with sections containing multiple
beads where the embolic effect would be more severe
(Fig. 4, black arrows). There was no evidence of necrosis
at either the 4 week or 12 week time points, as the tissue
has remodelled. Inﬂammation was similarly only very mild
(average score over all samples 0.25 ± 0.43) and again,
only observed at the 1 week time period.
At all time points alginate beads were observed within
arteries post mortem. Cellular inﬁltration and surface
roughness were infrequent but were observed at all time
points, for both bead types (Fig. 5). This demonstrated that
this method of degradation was not time nor bead speciﬁc.
Generally, if cellular inﬁltration did occur, the site was
often located near signs of thrombus, which is likely to
have been induced by embolisation. In addition, at all time
points, round smooth beads were found in the lumen of
arteries without signs of thrombus, inﬂammatory cells or
degradation (Fig. 5). This suggests that the beads were not
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Fig. 3 Change in M and G alginate gel beads a diameter (mean,
±SD, (n = 100)) and b hydrated weight (% original weight, ±max/
min, (n = 3)), in 1 ml Ringer’s solution at 37C for 12 weeks. The
Ringer’s solution was removed and replaced at each time point.
Initially, the size increased over the ﬁrst few days, but decreased back
to the original size after 4 weeks and then dropped below the original
size after 12 weeks
Fig. 4 Example of multiple beads (high G alginate) at 1 week, with
some areas of associated necrosis (arrows) surrounding the vessels
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123degrading simply due to their presence within the arterial
system. Some evidence of further degradation by extensive
cellular inﬁltration was observed at some, but not all, time
points. Some examples are given in (Fig. 6). None of the
alginate beads however, were fully degraded within
12 weeks.
The level of bead degradation 1, 4 and 12 weeks post-
implantation in vivo did not follow any trends with respect
to time (Fig. 5). In addition, degradation could not be
monitored by size as the sectioning was effectively random
so beads could not be shown to have been sliced at the
largest diameter, thereby making any comparison void. The
sample number was too low to overcome this.
4 Discussion
In embolic procedures the ease of delivery of the embolic is
imperative, unwanted catheter blockage adds time and
pressure to the process; limiting the control the interven-
tional radiologist has. The high purity, high molecular
weight alginate gel beads (both high G and high M)
showed good deliverability in vitro, and in vivo. The lack
of fragmentation will prevent any unwanted premature
embolisation due to particulates clumping together. The
data obtained from compression testing shows that neither
a higher G or M content has any signiﬁcant effect on the
compressibility of the alginate gel beads; the in vivo data
also showed no obvious difference between the two bead
types. The in vitro compressibility of the calcium cross-
linked high molecular weight alginate beads was most
similar to Bead Block, an embolic bead that is currently
used for UFE [25, 27].
The main physical difference between the in vitro setup
and the reality in vivo is the extent to which 1 ml repre-
sented the sink conditions in an embolisation capacity; this
is yet to be fully determined.
In vivo, inﬂammatory cell inﬁltration and bead surface
roughness appeared to be often thrombus-associated,
whereas the beads with smooth surfaces appeared to lack
this association. This suggests that whilst an alginate bead
can undergo degradation, this may be accelerated by the
inﬁltration of surrounding thrombus by inﬂammatory cells.
Some beads will be exposed to more thrombus than others
as a consequence of their relative position within the em-
bolised vessel; those more proximal or distal in the column
of occluding beads for instance. This accounts for the inter-
bead variability observed. The reorganisation of tissue and
bead degradation makes the system dynamic and in time
allows previously unexposed beads to become eventual
targets for inﬂammatory cells. Consequently, both pristine
and misshapen beads can be seen at all time points. When
compared to studies of a range of other embolic agents on
the impact on inﬂammatory tissue and foreign body reac-
tion in porcine liver [28] or kidney [29] models, our ﬁnd-
ings here were consistent with a low level inﬂammatory
reaction in the uterine arteries. The excellent overall tol-
erance of the alginate beads in vivo is an expected conse-
quence of the ultra-high purity alginate used to synthesise
the beads. These observations could be important when
considering new materials suitable for use in biodegradable
embolic devices.
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Fig. 5 Images of high G and
high M alginate beads after 1, 4
and 12 weeks in an
embolisation environment.
Examples of smooth and rough-
edged beads can be observed for
both types at all time points
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123In vitro degradation began to be observed after
12 weeks under pseudo embolisation conditions. Lang [30]
composed a table of the occlusion times and potential to
restore the blood vessel for embolic materials used in
transcatheter embolisation. Although this table illustrates
data for the occlusion of arteries of different sizes, it is
clear that 12 weeks degradation is long enough to maintain
the occlusion, but is probably too late to enable restoration
of vascular continuity within that blood vessel. In vivo
however, no signiﬁcant difference was noted between the
G or M beads with regards to size and neither showed signs
of degradation after 1, 4 and 12 weeks. The discrepancy
may be due to the biological environment to which an
embolised microsphere is exposed.
Compared to the 2–3 week degradation time of Gelfoam,
the in vitro degradation of 4–12 weeks may mean that these
alginate beads may be too permanent to restore vascular
connection. However, patients commonly express worries
about foreign materials remaining in the body in uterine
ﬁbroid embolisation [31] and whilst this may or may not be
a physiological problem, reduction of additional angst for
the patient is desirable. An embolic, made from what could
be considered a natural material, which can perform its
function and then be degraded and excreted from the body
over time, could be attractive to the patient. The alginate
beads tested here could offer this potential. The study pre-
sented here however, aimed to evaluate tissue reaction to
the alginate material and its degradation potential. Although
the mechanical properties of the alginate beads would
suggest that they have equivalent deformation properties to
other commercially available embolisation microspheres,
further work is required in an alternative relevant model to
understand the effectiveness of the embolisation procedure
and the tendency for recanalisation of the vessel.
5 Conclusions
High molecular weight alginate gel beads have been
evaluated in vitro and in vivo to establish whether their
physical properties show the capability to be considered as
an embolisation device. Both the in vitro and in vivo data
demonstrate good delivery, with no tendency to block
catheters or fragment owing to compressibility properties
comparable to current commercially-available embolic
beads. In vitro, swelling was noted almost immediately and
after 12 weeks the ﬁrst signs of degradation were observed,
although little difference was noted in vivo. This study has
shown that high molecular weight alginate gel beads are
well tolerated by the body, but beads susceptible to
inﬂammatory cell inﬁltration were more often associated
with surrounding thrombus. The thrombus presumably acts
as a focus for inﬂammatory cell inﬁltration during
remodelling of the vessel post embolisation. The beads
were shown to be easy to handle and were still observable
largely intact in histological sections after 3 months in
vivo. The beads handle well and are robust enough to be
delivered through a 2.7 Fr microcatheter, which is a com-
monly used product in UFE procedures. This study has
demonstrated that high molecular weight, high purity
alginate beads can be considered as semi-permanent em-
bolisation beads, with the potential to resorb over time.
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